title: A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
abstract: OBJECTIVE
  To compare the lipid and metabolic effects, efficacy, and safety of twice-daily regimens of Trizivir (abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg triple nucleoside tablet; TZV), Combivir (lamivudine 150 mg/zidovudine 300 mg combination tablet; COM)+nelfinavir (NFV), and stavudine (d4 T)+lamivudine (3TC)+NFV.
  
  
  METHODS
  An international, phase 4, open-label, parallel-group, 34-centre study was conducted in 254 non-diabetic, antiretroviral-naive, HIV-infected out-patients with an HIV-1 RNA level of >1000 HIV-1 RNA copies/mL and < or =200,000 copies/mL and a CD4 cell count of >50 cells/microL.
  
  
  METHODS
  Patients were randomized 1 : 1 : 1 to TZV twice daily (n = 85), COM/NFV 1250 mg twice daily (n = 88), or d4T 40 mg+3TC 150 mg+NFV 1250 mg twice daily (n = 81) for 96 weeks. Treatments were compared using analysis of covariance (ANCOVA) with regard to changes from baseline in fasting lipids in the total population and in sex and ethnic subgroups. The proportions of patients achieving HIV-1 RNA <50 and <400 copies/mL were compared using a 95% confidence interval (CI) on the difference between proportions.
  
  
  RESULTS
  The study population was diverse (50% female, 40% black and 37% Hispanic). Mean baseline low-density lipoprotein (LDL) cholesterol was 99 mg/dL, HIV-1 RNA was 4.43 log10 copies/mL and CD4 cell count was 355 cells/microL. At week 96, fasting LDL cholesterol changed minimally in the TZV group [least square mean (LSM) change from baseline, -8 mg/dL], but increased with d4T/3TC/NFV and COM/NFV (+29 and +19 mg/dL, respectively; P < 0.001 versus TZV). Week 96 LDL-cholesterol levels were significantly lower in the TZV group than in the other two treatment groups in women and men and lower than in the d4T/3TC/NFV group in Hispanic and black patients. In black patients, the week-96 LSM change from baseline in LDL cholesterol was significantly less with TZV than with d4T/3TC/NFV (+1 vs+39 mg/dL; P = 0.003). Total cholesterol >200 mg/dL occurred in a smaller proportion of patients receiving TZV (30%) compared with COM/NFV (50%) or d4T/3TC/NFV (60%; P = 0.005 vs TZV). High-density lipoprotein (HDL) cholesterol did not change markedly with any treatment. Although triglycerides increased, they changed least in women and Hispanic patients receiving TZV. Virological and CD4 responses to the treatments were similar in the total population and in the subgroups. Diarrhoea was reported more often in the NFV arms and nausea in the ZDV arms.
  
  
  CONCLUSIONS
  Over 96 weeks, TZV twice daily has significantly less effect on LDL cholesterol than COM/NFV or d4T/3TC/NFV twice daily, especially in women and black patients, and is associated with similar virological and CD4 responses.
authors.affiliation: Georgetown University Medical Center, Washington, DC 20007, USA. kumarp@gunet.georgetown.edu
authors.forename: P N
authors.initials: PN
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez-French
authors.forename: M A
authors.initials: MA
authors.lastname: Thompson
authors.forename: K T
authors.initials: KT
authors.lastname: Tashima
authors.forename: D
authors.initials: D
authors.lastname: Averitt
authors.forename: P G
authors.initials: PG
authors.lastname: Wannamaker
authors.forename: V C
authors.initials: VC
authors.lastname: Williams
authors.forename: M S
authors.initials: MS
authors.lastname: Shaefer
authors.forename: G E
authors.initials: GE
authors.lastname: Pakes
authors.forename: K A
authors.initials: KA
authors.lastname: Pappa
mesh_terms: D001741:Black or African American; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000208:ethnology / Q000821:virology; D015497:HIV-1; D006630:Hispanic or Latino; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D019344:Lactic Acid / Q000097:blood; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D019888:Nelfinavir / Q000009:adverse effects / Q000627:therapeutic use; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D012737:Sex Factors; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D002784:Cholesterol; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019344:Lactic Acid; D019259:Lamivudine; D019888:Nelfinavir; D019829:Nevirapine; D018119:Stavudine; D014280:Triglycerides; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir; C109078:lamivudine, zidovudine drug combination